Safe-haven flows into the Japanese yen this October show how quickly money can move when investors get nervous about risk. Cash that jumps in and out of markets can leave you whiplashed. Regular income from established dividend payers can help steady the ride. This piece highlights a small group of long-haul dividend payers with yields above 5%, and identifies three standouts from that list.
The stocks covered below are just a first pass, and the full Dividend Aristocrats screen on Simply Wall St surfaced another 222 high-yield candidates with equally compelling income stories that are not detailed here. To identify and analyze those higher conviction 5%+ opportunities for yourself, head straight into the Dividend Aristocrats screener
Dah Sing Banking Group (SEHK:2356)
Dah Sing Banking Group is a Hong Kong based lender that earns most of its money from mainstream banking, with about HK$3.7b from Personal Banking, HK$2.2b from Treasury and Global Markets, and HK$517m from Mainland China and Macau Banking, supporting its high cash dividends. The group's market cap is roughly HK$18.3b.
Dah Sing Banking Group aligns with the Dividend Aristocrats theme because its 5%+ yield is backed by core banking earnings, with net profit margins at 42.1% and net income of HK$1,780.48m for H1 2026. Income investors may focus on what happens if an unseen pressure on bad loans and dividend consistency shifts.
If you want to see whether those core earnings really underpin Dah Sing Banking Group's payout strength, go straight to the Dah Sing Banking Group financial health report
China Resources Pharmaceutical Group (SEHK:3320)
China Resources Pharmaceutical Group is a Hong Kong based healthcare group that manufactures drugs and runs a large Mainland China distribution and retail network, with CN¥222.7b from distribution, CN¥50.7b from manufacturing and CN¥13.0b from retail in 2026, supporting its HK$27.96b market value.
China Resources Pharmaceutical Group appeals to dividend hunters because a vast hospital and pharmacy distribution arm feeds recurring cash flow into a high yield profile, while a low 5.7x P/E and recent earnings momentum add support. The real test is how one unseen pressure on funding costs and payouts develops over time.
That funding pressure question makes the 5 key rewards and 1 important warning sign especially useful for seeing what might be quietly reshaping China Resources Pharmaceutical Group's dividend story.
Chow Sang Sang Holdings International (SEHK:116)
Chow Sang Sang Holdings International runs a long established jewellery group across Mainland China, Hong Kong, Macau and Taiwan, with HK$23.6b from Retail of Jewellery and Watches out of roughly HK$24.3b segment revenue, supported by smaller wholesale and trading units, and carries a market value of about HK$8.5b.
For a high yield dividend theme, Chow Sang Sang leans heavily on its jewellery and watch shops. These generated HK$12,878.09m in H1 2026 revenue and HK$2,152.64m net income, while the stock trades around 2.9x P/E compared with roughly 7.7x for Hong Kong luxury peers. This leaves investors focused on what happens if one unseen pressure around funding costs and future earnings shifts.
That funding shift risk is exactly why the 3 key rewards and 2 important warning signs (1 is major!) could be worth a look before Chow Sang Sang's income story starts to decouple from expectations.
Seeking Alternatives Before Everyone Else?
Fresh ideas move first. By the time momentum is flying, the best entry points may already be dropping out of reach. Scan these under the radar ideas now and get in early.
-
Spot dependable income candidates and track potential high yield opportunities with the 225 dividend fortresses before other investors start hunting for the same payouts.
-
Target potential growth stories in cutting edge computing by running through the curated 25 quantum computing stocks while the narrative is still forming and valuations have not been fully crowded out.
-
Lock in your watchlist of potential long term compounders by assessing the list of solid balance sheet and fundamentals (203 results) . This allows you to focus on balance sheets and fundamentals that may be overlooked by many market screens.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
